‘Low‐risk’ myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro‐ versus anti‐apoptotic bcl‐2‐related proteins

We performed flow cytometric analysis of CD34+ cell apoptosis in 59 patients with myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) secondary to MDS (MDS‐AML) using annexin V‐FITC, which binds to exposed phosphatidylserine on apoptotic cells. Apoptosis was significantly increased in FA...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology Vol. 103; no. 4; pp. 1075 - 1082
Main Authors: PARKER, J. E, FISHLOCK, K. L, MIJOVIC, A, CZEPULKOWSKI, B, PAGLIUCA, A, MUFTI, G. J
Format: Journal Article
Language:English
Published: Oxford, U.K. and Cambridge, USA Blackwell Science Ltd 01-12-1998
Blackwell
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract We performed flow cytometric analysis of CD34+ cell apoptosis in 59 patients with myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) secondary to MDS (MDS‐AML) using annexin V‐FITC, which binds to exposed phosphatidylserine on apoptotic cells. Apoptosis was significantly increased in FAB subtypes RA, RARS and RAEB (<10% blasts) (56.5% (15.1–86.5%)) compared to normal controls (18.5% (3.4–33.4%), P < 0.0001) and RAEB‐t/MDS‐AML (16% (2.1–43.2%), P < 0.0001). There was no correlation between % apoptosis, Full blood count or cytogenetics in any disease category. Two‐colour cytometric analysis of permeabilized CD34+ cells stained with antibodies to Bcl‐2, Bcl‐X (anti‐apoptotic), Bax and Bad (pro‐apoptotic), demonstrated significantly higher ratios of pro‐ v anti‐apoptotic proteins in early MDS (2.47 (1.19–9.42) compared to advanced disease (1.14 (0.06–3.32), P = 0.0001). Moreover, using repeated measures of variants (ANOVA), we found that variations between individual Bcl‐2‐related proteins differed significantly according to disease subtype (P < 0.0005). Our results confirm that CD34+ cell apoptosis was significantly increased in MDS subtypes RA and RARS and fell with disease progression. Early MDS was also associated with a significantly higher CD34+ cell pro‐ v anti‐apoptotic Bcl‐2‐family‐protein ratio than advanced disease. Furthermore, patterns of expression of individual Bcl‐2 related proteins differed significantly between different disease categories. However, no correlation between pro‐ v anti‐apoptotic Bcl‐2‐family‐protein ratios and the degree of apoptosis was observed.
AbstractList We performed flow cytometric analysis of CD34+ cell apoptosis in 59 patients with myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) secondary to MDS (MDS-AML) using annexin V-FITC, which binds to exposed phosphatidylserine on apoptotic cells. Apoptosis was significantly increased in FAB subtypes RA, RARS and RAEB (<10% blasts) (56.5% (15.1-86.5%)) compared to normal controls (18.5% (3.4-33.4%), P<0.0001) and RAEB-t/MDS-AML (16% (2.1-43.2%), P<0.0001). There was no correlation between % apoptosis, Full blood count or cytogenetics in any disease category. Two-colour cytometric analysis of permeabilized CD34+ cells stained with antibodies to Bcl-2, Bcl-X (anti-apoptotic), Bax and Bad (pro-apoptotic), demonstrated significantly higher ratios of pro- v anti-apoptotic proteins in early MDS (2.47 (1.19-9.42) compared to advanced disease (1.14 (0.06-3.32), P=0.0001). Moreover, using repeated measures of variants (ANOVA), we found that variations between individual Bcl-2-related proteins differed significantly according to disease subtype (P<0.0005). Our results confirm that CD34+ cell apoptosis was significantly increased in MDS subtypes RA and RARS and fell with disease progression. Early MDS was also associated with a significantly higher CD34+ cell pro- v anti-apoptotic Bcl-2-family-protein ratio than advanced disease. Furthermore, patterns of expression of individual Bcl-2 related proteins differed significantly between different disease categories. However, no correlation between pro- v anti-apoptotic Bcl-2-family-protein ratios and the degree of apoptosis was observed.
We performed flow cytometric analysis of CD34+ cell apoptosis in 59 patients with myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) secondary to MDS (MDS-AML) using annexin V-FITC, which binds to exposed phosphatidylserine on apoptotic cells. Apoptosis was significantly increased in FAB subtypes RA, RARS and RAEB (&lt;10% blasts) (56.5% (15.1-86.5%)) compared to normal controls (18.5% (3.4-33.4%), P&lt;0.0001) and RAEB-t/MDS-AML (16% (2.1-43.2%), P&lt;0.0001). There was no correlation between % apoptosis, Full blood count or cytogenetics in any disease category. Two-colour cytometric analysis of permeabilized CD34+ cells stained with antibodies to Bcl-2, Bcl-X (anti-apoptotic), Bax and Bad (pro-apoptotic), demonstrated significantly higher ratios of pro- v anti-apoptotic proteins in early MDS (2.47 (1.19-9.42) compared to advanced disease (1.14 (0.06-3.32), P=0.0001). Moreover, using repeated measures of variants (ANOVA), we found that variations between individual Bcl-2-related proteins differed significantly according to disease subtype (P&lt;0.0005). Our results confirm that CD34+ cell apoptosis was significantly increased in MDS subtypes RA and RARS and fell with disease progression. Early MDS was also associated with a significantly higher CD34+ cell pro- v anti-apoptotic Bcl-2-family-protein ratio than advanced disease. Furthermore, patterns of expression of individual Bcl-2 related proteins differed significantly between different disease categories. However, no correlation between pro- v anti-apoptotic Bcl-2-family-protein ratios and the degree of apoptosis was observed.
We performed flow cytometric analysis of CD34 + cell apoptosis in 59 patients with myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) secondary to MDS (MDS‐AML) using annexin V‐FITC, which binds to exposed phosphatidylserine on apoptotic cells. Apoptosis was significantly increased in FAB subtypes RA, RARS and RAEB (<10% blasts) (56.5% (15.1–86.5%)) compared to normal controls (18.5% (3.4–33.4%), P  < 0.0001) and RAEB‐t/MDS‐AML (16% (2.1–43.2%), P  < 0.0001). There was no correlation between % apoptosis, Full blood count or cytogenetics in any disease category. Two‐colour cytometric analysis of permeabilized CD34 + cells stained with antibodies to Bcl‐2, Bcl‐X (anti‐apoptotic), Bax and Bad (pro‐apoptotic), demonstrated significantly higher ratios of pro‐ v anti‐apoptotic proteins in early MDS (2.47 (1.19–9.42) compared to advanced disease (1.14 (0.06–3.32), P  = 0.0001). Moreover, using repeated measures of variants (ANOVA), we found that variations between individual Bcl‐2‐related proteins differed significantly according to disease subtype ( P  < 0.0005). Our results confirm that CD34 + cell apoptosis was significantly increased in MDS subtypes RA and RARS and fell with disease progression. Early MDS was also associated with a significantly higher CD34 + cell pro‐ v anti‐apoptotic Bcl‐2‐family‐protein ratio than advanced disease. Furthermore, patterns of expression of individual Bcl‐2 related proteins differed significantly between different disease categories. However, no correlation between pro‐ v anti‐apoptotic Bcl‐2‐family‐protein ratios and the degree of apoptosis was observed.
Author Mufti
Pagliuca
Fishlock
Mijovic
Czepulkowski
Parker
Author_xml – sequence: 1
  givenname: J. E
  surname: PARKER
  fullname: PARKER, J. E
  organization: King's College Hospital and School of Medicine and Dentistry, London, United Kingdom
– sequence: 2
  givenname: K. L
  surname: FISHLOCK
  fullname: FISHLOCK, K. L
  organization: King's College Hospital and School of Medicine and Dentistry, London, United Kingdom
– sequence: 3
  givenname: A
  surname: MIJOVIC
  fullname: MIJOVIC, A
  organization: King's College Hospital and School of Medicine and Dentistry, London, United Kingdom
– sequence: 4
  givenname: B
  surname: CZEPULKOWSKI
  fullname: CZEPULKOWSKI, B
  organization: King's College Hospital and School of Medicine and Dentistry, London, United Kingdom
– sequence: 5
  givenname: A
  surname: PAGLIUCA
  fullname: PAGLIUCA, A
  organization: King's College Hospital and School of Medicine and Dentistry, London, United Kingdom
– sequence: 6
  givenname: G. J
  surname: MUFTI
  fullname: MUFTI, G. J
  organization: King's College Hospital and School of Medicine and Dentistry, London, United Kingdom
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1618549$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/9886323$$D View this record in MEDLINE/PubMed
BookMark eNqNkcGO0zAURS00aOgMfAKSF4hdgl07jrNgASNgQJXYwNpynRfhksTBL502u34CS9jzZf0SnGk1bLFk2dY9911L94pc9KEHQihnOWdSvdrkXKgiW3LJc15VOmecc5nvH5HFg3BBFoyxMksG_YRcIW4Y44IV_JJcVlorsRQL8ud4-LUKu-PhZ_T4_Xj4TbsJ2lBPOLQWR-8oTn0dQwfUI7WIwXk7Qk13fvxGYe8A0d8BtUMYxoAz09dpU9-7CBYTGe3oAw0NHWJIOfQOIm5nbvTpeTLOQWvXpvdy_gq09xnJMILv8Sl53NgW4dn5vCZf37_7cnObrT5_-HjzZpU5KYXMFGu0KGpWlVLrUhaSrbWrkqIsL5VomFZWNaCEKivg0hWyYHzJRd24eg21Fdfk5WluCv6xBRxN59FB29oewhaNqrgo0kqgPoEuBsQIjRmi72ycDGdmLshszNyDmXswc0HmviCzT9bn54ztuoP6wXhuJOkvzrpFZ9sm2t55_DdfcV3IKmGvT9jOtzD9d7x5--l2vom_X1S3VA
CODEN BJHEAL
CitedBy_id crossref_primary_10_1038_nrc3321
crossref_primary_10_1038_sj_leu_2401959
crossref_primary_10_1182_blood_V95_12_3929_012k01_3929_3938
crossref_primary_10_1182_blood_V96_12_3932_h8003932_3932_3938
crossref_primary_10_1007_BF02826211
crossref_primary_10_1158_1078_0432_CCR_04_0598
crossref_primary_10_1007_BF03032653
crossref_primary_10_1016_j_exphem_2008_07_012
crossref_primary_10_1046_j_1365_2141_2001_02581_x
crossref_primary_10_1111_j_1365_2796_2008_02052_x
crossref_primary_10_1182_blood_2002_01_0096
crossref_primary_10_1182_bloodadvances_2020004094
crossref_primary_10_1292_jvms_62_1059
crossref_primary_10_1111_j_1582_4934_2003_tb00232_x
crossref_primary_10_1182_blood_V96_12_3932
crossref_primary_10_1007_s00277_009_0835_2
crossref_primary_10_1371_journal_pone_0165582
crossref_primary_10_1182_blood_2007_11_122028
crossref_primary_10_1038_s41375_021_01212_6
crossref_primary_10_1002_ajh_10108
crossref_primary_10_1016_j_leukres_2007_04_012
crossref_primary_10_1186_s12867_016_0071_y
crossref_primary_10_3109_10428190009054877
crossref_primary_10_3109_10428190109064605
crossref_primary_10_5858_2002_126_0255_TPE
crossref_primary_10_5858_2005_129_1299_MSCFPA
crossref_primary_10_1016_S0145_2126_02_00098_X
crossref_primary_10_1038_sj_leu_2402110
crossref_primary_10_1016_j_leukres_2019_03_006
crossref_primary_10_1634_theoncologist_2011_S3_35
crossref_primary_10_1016_j_leukres_2003_12_004
crossref_primary_10_1016_S0145_2126_99_00152_6
crossref_primary_10_1016_j_yexcr_2015_12_008
crossref_primary_10_1046_j_1365_2141_2001_02708_x
crossref_primary_10_1016_S0301_472X_00_00607_X
crossref_primary_10_1182_blood_2012_07_445635
crossref_primary_10_1007_s12094_010_0574_9
crossref_primary_10_1016_j_leukres_2009_03_027
crossref_primary_10_1080_10428190400027829
crossref_primary_10_1016_j_blre_2007_10_003
crossref_primary_10_1097_00001622_200001000_00003
crossref_primary_10_1016_j_exphem_2005_02_005
crossref_primary_10_1016_j_blre_2013_07_003
crossref_primary_10_1111_j_1365_2362_2004_01417_x
crossref_primary_10_1007_BF02994003
crossref_primary_10_1038_leu_2014_301
crossref_primary_10_1007_s12032_010_9678_x
crossref_primary_10_1016_j_arcmed_2003_09_001
crossref_primary_10_1016_S0145_2126_99_00094_6
crossref_primary_10_1038_s41598_018_32306_4
crossref_primary_10_1182_asheducation_2002_1_136
crossref_primary_10_1038_nrclinonc_2017_197
crossref_primary_10_1093_hmg_ddn113
crossref_primary_10_1002_jhm_2049
crossref_primary_10_1016_S0301_472X_00_00179_X
crossref_primary_10_1053_j_seminhematol_2007_11_006
crossref_primary_10_1111_bjh_14666
crossref_primary_10_3109_10428190109060340
crossref_primary_10_1182_blood_2004_05_2017
crossref_primary_10_1016_j_cbi_2017_05_014
crossref_primary_10_1139_bcb_2012_0109
crossref_primary_10_1016_j_leukres_2011_06_017
crossref_primary_10_26559_mersinsbd_581124
crossref_primary_10_1182_blood_V95_12_3929
crossref_primary_10_3390_ijms16010966
crossref_primary_10_1016_j_leukres_2011_02_025
crossref_primary_10_1038_sj_leu_2403021
crossref_primary_10_3892_ijo_2016_3689
crossref_primary_10_1182_blood_2002_06_1774
crossref_primary_10_1182_blood_2012_02_412379
crossref_primary_10_1016_S0145_2126_00_00151_X
crossref_primary_10_1182_blood_2004_06_2108
crossref_primary_10_1016_j_exphem_2006_08_017
Cites_doi 10.1182/blood.V88.11.4275.4275
10.1182/blood.V89.1.243
10.1016/0022-1759(95)00072-I
10.1038/sj.leu.2400640
10.1111/j.1365-2141.1982.tb02771.x
10.1182/blood.V81.11.3091.3091
10.1182/blood.V88.2.386.bloodjournal882386
10.1111/j.1365-2141.1991.tb08616.x
10.1038/sj.leu.2400980
10.7326/0003-4819-103-4-620
10.1182/blood.V79.5.1291.1291
10.1182/blood.V89.6.2079
10.1002/(SICI)1097-0320(19970901)29:1<28::AID-CYTO2>3.0.CO;2-9
10.1038/sj.leu.2400654
10.1016/S0145-2126(96)00110-5
10.1002/(SICI)1096-9896(199605)179:1<26::AID-PATH516>3.0.CO;2-E
10.3109/10428199709039010
10.1182/blood.V86.1.268.bloodjournal861268
10.1084/jem.182.5.1545
10.1182/blood.V84.5.1415.bloodjournal8451415
ContentType Journal Article
Copyright 1999 INIST-CNRS
Copyright_xml – notice: 1999 INIST-CNRS
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1046/j.1365-2141.1998.01114.x
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
CrossRef

Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1365-2141
EndPage 1082
ExternalDocumentID 10_1046_j_1365_2141_1998_01114_x
9886323
1618549
BJH1114
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1KJ
1OB
1OC
23N
24P
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
6J9
6P2
702
7PT
8-0
8-1
8-3
8-4
8-5
8F7
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAKAS
AANLZ
AAONW
AASGY
AAXRX
AAYEP
AAZKR
ABCQN
ABCUV
ABEML
ABJNI
ABLJU
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AHEFC
AI.
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EGARE
EJD
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IH2
IHE
IX1
J0M
J5H
K48
KBYEO
L7B
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N4W
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
TEORI
UB1
V8K
V9Y
VH1
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
X7M
XG1
YFH
YOC
YUY
ZGI
ZXP
ZZTAW
~IA
~WT
08R
AAJUZ
AAPBV
AAVGM
ABCVL
ABFLS
ABHUG
ABPTK
ABWRO
ACXME
ADAWD
ADDAD
ADGIM
AFVGU
AGJLS
IPNFZ
IQODW
UMP
ZA5
CGR
CUY
CVF
ECM
EIF
NPM
AAMNL
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c4434-60f835d09748874540b8c94346a1763f086a6fe63679e14c54501213dfcdbeda3
IEDL.DBID 33P
ISSN 0007-1048
IngestDate Fri Aug 16 09:51:29 EDT 2024
Fri Nov 22 00:42:56 EST 2024
Sat Sep 28 08:36:16 EDT 2024
Fri Nov 25 01:03:26 EST 2022
Sat Aug 24 01:03:42 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Human
Flow cytometry
Fluorescent labelling
Cell death
Pathogenesis
Gene product
C-Onc gene
Genetics
Malignant hemopathy
Myelodysplastic syndrome
Protooncogene
Apoptosis
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4434-60f835d09748874540b8c94346a1763f086a6fe63679e14c54501213dfcdbeda3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://doi.org/10.1046/j.1365-2141.1998.01114.x
PMID 9886323
PQID 69135555
PQPubID 23479
PageCount 8
ParticipantIDs proquest_miscellaneous_69135555
crossref_primary_10_1046_j_1365_2141_1998_01114_x
pubmed_primary_9886323
pascalfrancis_primary_1618549
wiley_primary_10_1046_j_1365_2141_1998_01114_x_BJH1114
PublicationCentury 1900
PublicationDate December 1998
PublicationDateYYYYMMDD 1998-12-01
PublicationDate_xml – month: 12
  year: 1998
  text: December 1998
PublicationDecade 1990
PublicationPlace Oxford, U.K. and Cambridge, USA
PublicationPlace_xml – name: Oxford, U.K. and Cambridge, USA
– name: Oxford
– name: England
PublicationTitle British journal of haematology
PublicationTitleAlternate Br J Haematol
PublicationYear 1998
Publisher Blackwell Science Ltd
Blackwell
Publisher_xml – name: Blackwell Science Ltd
– name: Blackwell
References 1993; 7
1998; 26
1989; 4
1997; 21
1982; 51
1993; 81
1991; 77
1997; 24
1997; 89
1986; 15
1997; 29
1985; 103
1992; 79
1996; 148
1996; 10
1994; 84
1995; 86
1997; 90
1995; 40
1997; 11
1996; 179
1995; 184
1998; 12
1995; 182
1996; 88
Ter‐Harmsel B. (e_1_2_6_27_2) 1996; 179
Krajewska M. (e_1_2_6_19_2) 1996; 148
e_1_2_6_30_2
Lima M. (e_1_2_6_20_2) 1995; 40
Cortelezzi A. (e_1_2_6_9_2) 1996; 88
Yoshida Y. (e_1_2_6_31_2) 1993; 7
Kliche K.O. (e_1_2_6_17_2) 1997; 90
e_1_2_6_18_2
Greenberg P.L. (e_1_2_6_14_2) 1994; 84
e_1_2_6_12_2
e_1_2_6_13_2
e_1_2_6_10_2
e_1_2_6_16_2
De‐Witte T. (e_1_2_6_11_2) 1989; 4
Mufti G.J. (e_1_2_6_22_2) 1986; 15
e_1_2_6_15_2
Stoetzer O.J. (e_1_2_6_26_2) 1996; 10
e_1_2_6_8_2
e_1_2_6_7_2
e_1_2_6_29_2
e_1_2_6_4_2
e_1_2_6_3_2
e_1_2_6_6_2
e_1_2_6_5_2
e_1_2_6_24_2
e_1_2_6_23_2
Traycoff C.M. (e_1_2_6_28_2) 1998; 26
e_1_2_6_2_2
e_1_2_6_21_2
e_1_2_6_25_2
References_xml – volume: 84,
  start-page: 1415
  year: 1994
  end-page: 1420
  article-title: Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis
  publication-title: Blood
– volume: 11,
  start-page: 656
  year: 1997
  end-page: 659
  article-title: Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment
  publication-title: Leukemia
– volume: 77,
  start-page: 497
  year: 1991
  end-page: 501
  article-title: Prognostic factors in adult myelodysplastic syndromes treated by intensive chemotherapy
  publication-title: British Journal of Haematology
– volume: 184,
  start-page: 39
  year: 1995
  end-page: 51
  article-title: A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V
  publication-title: Journal of Immunological Methods
– volume: 103,
  start-page: 620
  year: 1985
  end-page: 625
  article-title: Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French–American–British Cooperative Group
  publication-title: Annals of Internal Medicine
– volume: 7,
  start-page: 144
  year: 1993
  end-page: 146
  article-title: Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome
  publication-title: Leukemia
– volume: 79,
  start-page: 1291
  year: 1992
  end-page: 1298
  article-title: Bcl‐2 proto‐oncogene expression in normal and neoplastic human myeloid cells
  publication-title: Blood
– volume: 10,
  start-page: S18
  year: 1996
  end-page: S22
  article-title: Association of bcl‐2, bax, bcl‐xL and interleukin‐1 beta‐converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia
  publication-title: Leukemia
– volume: 12,
  start-page: 486
  year: 1998
  end-page: 492
  article-title: Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia
  publication-title: Leukemia
– volume: 88,
  start-page: 386
  year: 1996
  end-page: 401
  article-title: Molecular thanatopsis: a discourse on the BCL2 family and cell death
  publication-title: Blood
– volume: 179,
  start-page: 26
  year: 1996
  end-page: 30
  article-title: BCL‐2 immunoreactivity increases with severity of CIN: a study of normal cervical epithelia, CIN, and cervical carcinoma
  publication-title: Journal of Pathology
– volume: 81,
  start-page: 3091
  year: 1993
  end-page: 3096
  article-title: High expression of bcl‐2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy
  publication-title: Blood
– volume: 88,
  start-page: 4275
  year: 1996
  end-page: 4287
  article-title: Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells
  publication-title: Blood
– volume: 4,
  start-page: 33
  year: 1989
  end-page: 35
  article-title: Intensive chemotherapy for patients with myelodysplastic syndromes and acute myelogenous leukemia younger than 65 years
  publication-title: Bone Marrow Transplantation
– volume: 89,
  start-page: 2079
  year: 1997
  end-page: 2088
  article-title: International scoring system for evaluating prognosis in myelodysplastic syndromes
  publication-title: Blood
– volume: 88,
  start-page: 95a
  year: 1996
  article-title: Apoptosis in myelodysplastic syndromes (MDS): putative role of the Bcl‐2 proto‐oncogene
  publication-title: Blood
– volume: 15,
  start-page: 953
  year: 1986
  end-page: 971
  article-title: Myelodysplastic syndromes: natural history and features of prognostic importance
  publication-title: Clinical Haematology
– volume: 86,
  start-page: 268
  year: 1995
  end-page: 276
  article-title: Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes
  publication-title: Blood
– volume: 89,
  start-page: 243
  year: 1997
  end-page: 255
  article-title: Measurement of spontaneous and therapeutic agent‐induced apoptosis with BCL‐2 protein expression in acute myeloid leukemia
  publication-title: Blood
– volume: 90,
  start-page: 202a
  year: 1997
  article-title: High expression of phosphatidylserine (PS) in MDS, secondary AML (sAML) and normal pro‐genitors: comparison with primary AML (pAML)
  publication-title: Blood
– volume: 148,
  start-page: 1567
  year: 1996
  end-page: 1576
  article-title: Immunohistochemical analysis of bcl‐2, bax, bcl‐x, and mcl‐1 expression in prostate cancers
  publication-title: American Journal of Pathology
– volume: 11,
  start-page: 839
  year: 1997
  end-page: 845
  article-title: Fas/Apo‐1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes
  publication-title: Leukemia
– volume: 84,
  start-page: 159a
  year: 1994
  article-title: Apoptosis in myelodysplastic syndrome (MDS)
  publication-title: Blood
– volume: 29,
  start-page: 28
  year: 1997
  end-page: 33
  article-title: Annexin‐V and TUNEL use in monitoring the progression of apoptosis in plants
  publication-title: Cytometry
– volume: 40,
  start-page: 49
  year: 1995
  end-page: 52
  article-title: Immunophenotypic characteristics of acute leukaemia after myelodysplastic syndromes
  publication-title: Sangre (Barcelona)
– volume: 51,
  start-page: 189
  year: 1982
  end-page: 199
  article-title: Proposals for the classification of the myelodysplastic syndromes
  publication-title: British Journal of Haematology
– volume: 182,
  start-page: 1545
  year: 1995
  end-page: 1556
  article-title: Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl‐2 and Abl
  publication-title: Journal of Experimental Medicine
– volume: 24,
  start-page: 221
  year: 1997
  end-page: 228
  article-title: Bcl‐2 expression in acute myeloblastic leukaemia: relationship with autonomous growth and CD34 antigen expression
  publication-title: Leukemia and Lymphoma
– volume: 26,
  start-page: 53
  year: 1998
  end-page: 62
  article-title: Proliferation‐induced decline of primitive hematopoietic progenitor cell activity is coupled with an increase in apoptosis of ex vivo expanded CD34 cells
  publication-title: Experimental Hematology
– volume: 21,
  start-page: 415
  year: 1997
  end-page: 425
  article-title: Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte‐CSF and erythropoietin
  publication-title: Leukemia Research
– ident: e_1_2_6_24_2
  doi: 10.1182/blood.V88.11.4275.4275
– ident: e_1_2_6_2_2
  doi: 10.1182/blood.V89.1.243
– ident: e_1_2_6_29_2
  doi: 10.1016/0022-1759(95)00072-I
– volume: 4
  start-page: 33
  year: 1989
  ident: e_1_2_6_11_2
  article-title: Intensive chemotherapy for patients with myelodysplastic syndromes and acute myelogenous leukemia younger than 65 years
  publication-title: Bone Marrow Transplantation
  contributor:
    fullname: De‐Witte T.
– volume: 10
  start-page: S18
  year: 1996
  ident: e_1_2_6_26_2
  article-title: Association of bcl‐2, bax, bcl‐xL and interleukin‐1 beta‐converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia
  publication-title: Leukemia
  contributor:
    fullname: Stoetzer O.J.
– volume: 7
  start-page: 144
  year: 1993
  ident: e_1_2_6_31_2
  article-title: Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome
  publication-title: Leukemia
  contributor:
    fullname: Yoshida Y.
– ident: e_1_2_6_5_2
  doi: 10.1038/sj.leu.2400640
– ident: e_1_2_6_3_2
  doi: 10.1111/j.1365-2141.1982.tb02771.x
– ident: e_1_2_6_8_2
  doi: 10.1182/blood.V81.11.3091.3091
– ident: e_1_2_6_30_2
  doi: 10.1182/blood.V88.2.386.bloodjournal882386
– ident: e_1_2_6_12_2
  doi: 10.1111/j.1365-2141.1991.tb08616.x
– ident: e_1_2_6_16_2
  doi: 10.1038/sj.leu.2400980
– ident: e_1_2_6_4_2
  doi: 10.7326/0003-4819-103-4-620
– ident: e_1_2_6_10_2
  doi: 10.1182/blood.V79.5.1291.1291
– volume: 148
  start-page: 1567
  year: 1996
  ident: e_1_2_6_19_2
  article-title: Immunohistochemical analysis of bcl‐2, bax, bcl‐x, and mcl‐1 expression in prostate cancers
  publication-title: American Journal of Pathology
  contributor:
    fullname: Krajewska M.
– volume: 88
  start-page: 95a
  year: 1996
  ident: e_1_2_6_9_2
  article-title: Apoptosis in myelodysplastic syndromes (MDS): putative role of the Bcl‐2 proto‐oncogene
  publication-title: Blood
  contributor:
    fullname: Cortelezzi A.
– ident: e_1_2_6_13_2
  doi: 10.1182/blood.V89.6.2079
– ident: e_1_2_6_23_2
  doi: 10.1002/(SICI)1097-0320(19970901)29:1<28::AID-CYTO2>3.0.CO;2-9
– ident: e_1_2_6_6_2
  doi: 10.1038/sj.leu.2400654
– volume: 15
  start-page: 953
  year: 1986
  ident: e_1_2_6_22_2
  article-title: Myelodysplastic syndromes: natural history and features of prognostic importance
  publication-title: Clinical Haematology
  contributor:
    fullname: Mufti G.J.
– volume: 26
  start-page: 53
  year: 1998
  ident: e_1_2_6_28_2
  article-title: Proliferation‐induced decline of primitive hematopoietic progenitor cell activity is coupled with an increase in apoptosis of ex vivo expanded CD34+ cells
  publication-title: Experimental Hematology
  contributor:
    fullname: Traycoff C.M.
– ident: e_1_2_6_15_2
  doi: 10.1016/S0145-2126(96)00110-5
– volume: 179
  start-page: 26
  year: 1996
  ident: e_1_2_6_27_2
  article-title: BCL‐2 immunoreactivity increases with severity of CIN: a study of normal cervical epithelia, CIN, and cervical carcinoma
  publication-title: Journal of Pathology
  doi: 10.1002/(SICI)1096-9896(199605)179:1<26::AID-PATH516>3.0.CO;2-E
  contributor:
    fullname: Ter‐Harmsel B.
– volume: 40
  start-page: 49
  year: 1995
  ident: e_1_2_6_20_2
  article-title: Immunophenotypic characteristics of acute leukaemia after myelodysplastic syndromes
  publication-title: Sangre (Barcelona)
  contributor:
    fullname: Lima M.
– ident: e_1_2_6_7_2
  doi: 10.3109/10428199709039010
– ident: e_1_2_6_25_2
  doi: 10.1182/blood.V86.1.268.bloodjournal861268
– ident: e_1_2_6_21_2
  doi: 10.1084/jem.182.5.1545
– ident: e_1_2_6_18_2
  doi: 10.1182/blood.V84.5.1415.bloodjournal8451415
– volume: 84
  start-page: 159a
  year: 1994
  ident: e_1_2_6_14_2
  article-title: Apoptosis in myelodysplastic syndrome (MDS)
  publication-title: Blood
  contributor:
    fullname: Greenberg P.L.
– volume: 90
  start-page: 202a
  year: 1997
  ident: e_1_2_6_17_2
  article-title: High expression of phosphatidylserine (PS) in MDS, secondary AML (sAML) and normal pro‐genitors: comparison with primary AML (pAML)
  publication-title: Blood
  contributor:
    fullname: Kliche K.O.
SSID ssj0013051
Score 1.9494445
Snippet We performed flow cytometric analysis of CD34+ cell apoptosis in 59 patients with myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) secondary to...
We performed flow cytometric analysis of CD34 + cell apoptosis in 59 patients with myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) secondary to...
SourceID proquest
crossref
pubmed
pascalfrancis
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage 1075
SubjectTerms Acute Disease
acute myeloid leukaemia
Adult
Aged
Aged, 80 and over
Annexin A5 - metabolism
annexin V
Antigens, CD34 - metabolism
apoptosis
Apoptosis - physiology
Bcl‐2
Biological and medical sciences
Female
Flow Cytometry
Hematologic and hematopoietic diseases
Humans
Leukemia, Myeloid - metabolism
Leukemia, Myeloid - pathology
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Male
Medical sciences
Middle Aged
myelodysplastic syndrome
Myelodysplastic Syndromes - metabolism
Myelodysplastic Syndromes - pathology
Proto-Oncogene Proteins c-bcl-2 - metabolism
Title ‘Low‐risk’ myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro‐ versus anti‐apoptotic bcl‐2‐related proteins
URI https://onlinelibrary.wiley.com/doi/abs/10.1046%2Fj.1365-2141.1998.01114.x
https://www.ncbi.nlm.nih.gov/pubmed/9886323
https://search.proquest.com/docview/69135555
Volume 103
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NatwwEBZNDqUQkv6FuGlSHXp1sNdjyT42fywhKYW20JuwLAkWUtvEu2Rz20fosb33yfZJMiPbCQs5hJDDwho0a-94NPqkmfmGsc8AkTNS6tBogBBSZ8Pc-vwnY8DikiY1HWWPv8uvv7LjE6LJORtqYTp-iLsDN5oZ3l_TBC9014Uk8uy2Q4ZWDDGV3GUH1DUdDghP4qbBV3Mk3-4DClHaN8-T6Hkg65N6-gDngz-0slJtNEWLSnNdt4uH4OgquvXL0-nWc_6x12yzB6n8S2dVb9gLW71lLy_6MPw79n-5-HteXy8Xfygzfbn4x3_f2Mva3LQNgnEU4gMRAp-0vOgtwBpOp77czqk0Ab0sL5q6mdYtjakMfvikIhDb4khvmLx2HDWA9-GUPTKjcdMJXnaCdCNdXuL1iB6F0vpQ0jNPTKr2Pft5evLjaBz27R7CEiCBUEQO4aCJcIeTEQk_RDorib5OFDF6QYebr0I4KxIh0ZygROznCemMK422pki22XpVV3YHX60AW47ApSMhIdfktqSNSpOKzElndcDi4dWqpmP1UD4aD1S5RupXpH5F6lde_WoesL0VG7gXFIh5IA_Yp8EmFE5RirsUla1nrRJ5jKguTQO23ZnKnWieZSIZJQET3iAe_Szq8GxM3z48VXCXvfLFlT4v5yNbn17N7B5ba81s38-bW-AxHYw
link.rule.ids 315,782,786,1408,27933,27934,46064,46488
linkProvider Wiley-Blackwell
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Pa9RAFH9oBRXE_8VUa-fgNTXZvMwkR1tbVrstghW8DUlmBhZqEswutrf9CB717ifbT9L3JtmWhR5EPAQ2MC_Jvvzem1_m_RmAN4iRM0qVoSkRQ0ydDXPr85-MQUtTmip5KXv8WZ18zd4fcJuco1UtTN8f4mrBjS3D-2s2cF6QfjuEJXsr9ylaMcZcc5ft8rbpuEuE8g5KwiXXcySfrkMKUTpsn6fI92A2pPUMIc4br7Q2Vz1oi47U5vr9Lm4ipOv81k9Qh4_-6197DA8Hnire9cB6Ards_RTuHg-R-GfwZ7n4NWl-LBc_OTl9ufgtvl3Ys8ZcdC3xcRISq14IYtqJYgCBNYIXfoU95-oEcrSiaJt21nQ8pjZ0iGnNPLajkR6bonGCVED3EZxAMudxsymd9oJ8o7I6o_MRPwpn9pGkbz4xrbvn8OXw4HR_HA47PoQVYoKhjBwxQhPRR07GffgxKrOKO9jJIiZH6Oj7q5DOykQqQhRWRP98TzrjKlNaUySbsFE3tX1B71airUbo0pFUmJfsuZSNKpPKzClnywDi1bvVbd_YQ_uAPHLxGqtfs_o1q1979evzALbXQHAtKIn2YB7AzgoUmqyUQy9FbZt5p2UeE7FL0wA2e6xcieZZJpNREoD0iPjrZ9F7H8f8a-tfBXfg3vj0eKInH06OXsJ9X2vp03Rewcbs-9xuw-3OzF97I7oEzNQhtA
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1fa9RAEB-0QhHE-q8Ybe0--JqaXCa7yaO2Pc5aS0EF35YkuwsHNQnmDtu3-wg-6ruf7D5JZza5loM-iPgQuMBOkpvMzP6yM_NbgNeIkTNKlaEpEUNMnQ1z6-ufjEFLU5oqeSl78kmdfs0Oj5gm53jVC9PzQ1wvuLFn-HjNDt4a92bISvZO7iu0Yoy55S7b513TcZ_w5D0kVM48-klydpNRiNJh9zxFoQezoapnyHDeeqW1qepBW3SkNddvd3EbHl2Ht35-Gm_9z3_2CB4OKFW87c3qMdyx9RPY_Djk4Z_Cn-Xi10nzY7n4yaXpy8Vv8e3SnjfmsmsJjZOQWDEhiGknisEErBG87CvsBfcmUJgVRdu0s6bjMbWhQ0xrRrEdjfSWKRonSAN0H8HlI3MeN5vSaS_INyqrczof8aNwXR9JeuqJad09gy_jo88Hk3DY7yGsEBMMZeQID5qIPnEyZuHHqMwq5q-TRUxh0NHXVyGdlYlUZE9YEfjzjHTGVaa0pki2YaNuavucXq1EW43QpSOpMC85bikbVSaVmVPOlgHEq1er257WQ_t0PHLrGqtfs_o1q1979euLAHbXbOBGUBLowTyAvZVNaPJRTrwUtW3mnZZ5TLAuTQPY7k3lWjTPMpmMkgCkN4i_fhb97njCv178q-AebJ4djvXJ-9MPL-G-b7T0NTo7sDH7Pre7cLcz81feha4AMyIgWg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E2%80%98Low%E2%80%90risk%E2%80%99+myelodysplastic+syndrome+is+associated+with+excessive+apoptosis+and+an+increased+ratio+of+pro%E2%80%90+versus+anti%E2%80%90apoptotic+bcl%E2%80%902%E2%80%90related+proteins&rft.jtitle=British+journal+of+haematology&rft.au=Parker&rft.au=Fishlock&rft.au=Mijovic&rft.au=Czepulkowski&rft.date=1998-12-01&rft.pub=Blackwell+Science+Ltd&rft.issn=0007-1048&rft.eissn=1365-2141&rft.volume=103&rft.issue=4&rft.spage=1075&rft.epage=1082&rft_id=info:doi/10.1046%2Fj.1365-2141.1998.01114.x&rft.externalDBID=10.1046%252Fj.1365-2141.1998.01114.x&rft.externalDocID=BJH1114
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1048&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1048&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1048&client=summon